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The project and the team 
 
This project formed part of the Prison Health Research Network and was commissioned 
by the NHS National R & D Programme on Forensic Mental Health as one of the four 
demonstration projects, run under the auspices of the Network. It brought together 
researchers from two participating Universities in the Network. Richard Gray (Institute of 
Psychiatry (IoP), King’s College, London and Judith Lathlean, School of Nursing and 
Midwifery (SoNaM), University of Southampton were the Co-Principal Investigators. 
Alice Mills (SoNaM) was the Research Fellow responsible for data collection and 
analysis in the two Southern England sites, assisted in data collection by Will Van 
Veenhuyzen, a senior registrar from Ravenswood Medium Secure Unit. Dan Bressington 
(formerly IoP, now Canterbury Christ Church University) was the Researcher in the 
London site. Dr Andrew Forrester (HMP Brixton) greatly facilitated access to 
respondents in one of the sites and Dr Luke Birmingham (University of Southampton) 
also provided advice on the project.  
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Executive Summary 
Background 
Antipsychotic medication is an effective treatment for people with schizophrenia and 
schizoaffective disorder. Poor adherence with antipsychotic medication is a major 
preventable cause of increased symptoms and relapse, and can also result in re-
hospitalisation, high economic costs, poor outcomes (Perkins, 2002), and in forensic 
settings, violent and disturbed behaviour. Estimates of non-adherence rates of patients 
with psychosis vary dramatically, ranging from 24 to 90%.  
 
Similar rates of non-adherence with treatment are seen in prison environments and in the 
community, irrespective of the type of treatment being offered. The research literature on 
adherence amongst community populations has identified several factors that can 
influence adherence to antipsychotic medication, including substance misuse, medication 
side-effects, relationships with healthcare professionals and medication insight. However, 
no high quality empirical studies have examined adherence with antipsychotic medication 
in people with schizophrenia or schizoaffective disorder in prison, despite the high 
prevalence of psychosis among prisoners. This research was thus designed as a pilot 
study to explore adherence and satisfaction with antipsychotic medication among 
prisoners.  
 
Aims 
This pilot project has aimed to:  
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• Estimate the point prevalence of non-adherence to (typical/atypical) antipsychotic 
medication in population of people with schizophrenia or schizoaffective disorder 
in prison. 
• Determine prisoners’ satisfaction with and beliefs and attitudes towards 
antipsychotic medication.  
• Determine predictors of adherence in prisoners with schizophrenia or schizo-
affective disorder.      
• Compare the prevalence of adherence with a community sample of individuals 
with schizophrenia. 
• Explore patients’ current and previous subjective experiences of medication 
(embedded qualitative element of project) 
 
Research design  
The research took place in three prisons (HMP Brixton (adult male local prison), HMP 
Winchester (adult male local and category C prison) and HMP Bronzefield (adult female 
local prison), which were chosen to ensure that a variety of prisoners could be included in 
the study. To be eligible to take part in the research, participants needed to have been in 
prison for at least a month, have been prescribed antipsychotic medication for at least 
four weeks and be aged over 18 years. Forty-four prisoners were included in the study. 
 
An observational cross sectional survey design was used and data were collected through 
two main methods: 
 5
• Interviews with individual participants, which incorporated a range of self-report 
and interviewer-rated clinical measures to estimate the prevalence of adherence to 
antipsychotic medication and to determine prisoners’ satisfaction, beliefs and 
attitudes towards their medication, and a short qualitative interview section to 
explore participants’ past and current subjective experiences of medication. 
• Analysis of case notes such as Inmate Medical Records (IMRs) to collect 
information about various potential predictors of adherence such as offence and 
prison characteristics, clinical diagnoses and previous psychiatric history.  
Data from the clinical measures and case note analysis were analysed using SPSS to 
produce descriptive statistics and a final statistical model. Data from the qualitative 
interviews were analysed using simple qualitative content analysis.  
 
Summary of main findings 
Findings from the clinical measures and case note analysis 
• The majority of prisoners were prescribed antipsychotic medication for the 
treatment of a psychotic disorder (n=38, 86%), with six participants (14%) being 
prescribed antipsychotic medication for personality disorder. Most prisoners were 
prescribed second generation antipsychotic medication (n=28, 64%).  
• Results from the composite measure of adherence suggest that this population was 
passively accepting of medication, and that adherence rates were similar or 
slightly better than those seen in community samples of people with psychosis. 
• The sample population had good insight and generally positive attitudes towards 
treatment. Scores for the Satisfaction with Antipsychotic Medication (SWAM) 
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scale suggest that this population was also generally satisfied with their 
medication.  
• This population suffered more side effects than community samples of people 
with psychosis, despite being prescribed relatively modest levels of 
antipsychotics.  
• Adherence was found to be correlated significantly and positively with global 
insight, acceptance of the need for treatment, treatment attitudes, treatment 
acceptability, and miscellaneous side effects.  
• Adherence was significantly and negatively correlated with prisoners being in 
possession of their medication and medication insight on the SWAM scale.  
• Participants taking antipsychotic medication orally were significantly more 
adherent than those who were administered their medication via a long acting 
depot.  
• A stepwise linear regression analysis demonstrated that treatment acceptability 
and miscellaneous side effects were the only significant contributors towards 
adherence. A second stepwise linear regression analysis showed that two of the 
SWAM items on the treatment acceptability subscale (‘I feel motivated to take my 
antipsychotic medication’ and ‘my antipsychotic medication makes me feel 
better’) and the side effect of putting on weight accounted for 52% of the 
variance.  
 
Findings from the qualitative interviews 
• Many participants mentioned the positive effects of their medication (easing 
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psychotic symptoms, reducing anxiety) which had motivated them to take it and 
would continue to do so in the future. 
• Participants had mixed opinions about side effects. Just over a third felt that they 
had to tolerate them in order to reap the benefits of the medication. Other found 
them intensely distressing and this had influenced their willingness to comply 
with medication in the past. 
• Several prisoners whose medication was administered by staff reported being 
prevented from taking their medication as they were elsewhere in the prison (e.g. 
collecting meals, attending appointments) when it was being distributed.  
• Just over half of the participants reported previous non-compliance with their 
medication, particularly in the community before they came into prison. Some 
simply forgot or were careless about taking their medication, often because use of 
other substances took priority. 
• The routine of prison life could be beneficial in promoting adherence, particularly 
for those individuals who led chaotic lifestyles outside. 
• Prisons do not fall under the Mental Health Act 1983 and treatment cannot be 
forcibly administered. When participants did not want to take their medication, 
they often simply refused to do so. Few reported being offered incentives or 
threatened with punishment if they did not take their medication.  
• Two-thirds of prisoners reported that no-one had ever explained their medication 
to them. Without this knowledge, patients may find it difficult to trust mental 
health professionals and may become suspicious of their motives. 
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• The majority of respondents felt that their relationships with mental health 
professionals were good as they felt professionals listened to and acknowledged 
their concerns. 
• Where relationships were viewed negatively, prisoners felt that their psychiatrist 
did not share their understanding of their mental health problems, or thought that 
they did not have enough time with their psychiatrist or CPN.  
• Suggestions for improvements to their care included more time with mental health 
staff and more psychological input to help them deal with the issues they felt had 
led them to be on medication in the first instance. 
 
Discussion 
• The clinical characteristics of the prisoners in this sample were similar to those in 
community samples of people with schizophrenia in terms of type of medication 
prescribed, symptoms (Gray et al. 2005), satisfaction (Rofail et al. 2005), and 
insight (Mutsata et al. 2006). However, prisoners in this sample had more positive 
attitudes towards treatment and reported more side effects than in community 
samples (Gray et al. 2004; Gray et al. 2005), although such side effects did not 
appear to affect adherence. 
• Recognition of the need for treatment was correlated with adherence and 
interventions to enhance adherence are more likely to be effective if they focus on 
helping prisoners recognise this need, which may be assisted by strong, positive 
therapeutic relationships with healthcare professionals.  
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• Motivation to take medication and perceived treatment efficacy emerged as 
explanatory variables in the regression model, and this is supported by the 
qualitative data which suggest that many participants valued their medication for 
its positive effects on their mental health. At a clinical level it suggests that 
interventions to enhance adherence should focus on helping prisoners recognise 
the benefits of medication.  
• ‘Putting on weight’ was also a significant explanatory variable for adherence 
amongst this sample. However, weight gain was not objectively assessed, and it 
may be the consequence of other factors such as the prison diet and lack of 
exercise rather than a medication side effect. 
• The nature of the prison environment may have an influence on how adverse 
effects are perceived by prisoners as they may have a different impact on quality 
of life than treatment in the general population. The lack of meaningful activity 
and associated boredom may result in prisoners welcoming sedation as a side 
effect. Similarly, other side effects that would normally impact on functioning in 
the general population (e.g. weight gain) may not have such a marked effect in the 
prison population. 
• One of the major limitations of this study, however, is possible bias in the 
recruitment of the sample. This was a convenience and not a representative, 
random sample, and consequently our adherence estimates in this population may 
be overly optimistic. 
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Conclusion 
In our model adherence to antipsychotic medication was explained by the perceived 
efficacy of treatment, motivation to take medication and weight gain. Interventions to 
enhance adherence with treatment in prisons should aim to improve the prisoners’ 
perceptions of treatment efficacy and the need for treatment, establish a trusting 
collaborative working relationship with mental health professionals, minimise practical 
problems collecting medication, address long-term substance misuse and explore/manage 
side effects.  
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Introduction  
The Office for National Statistics prison survey (Singleton et al, 1998) found that, in a 
representative sample of 3000 prisoners, 9 out of 10 displayed signs of mental health 
problems with 10% of men and 14% of women demonstrating signs of psychosis. 
Antipsychotic medication is an effective treatment for people with schizophrenia and 
schizoaffective disorder. Poor adherence with antipsychotic medication is a major 
preventable cause of increased symptoms and relapse.  
 
Members of the project team had identified adherence to medication as a possible 
problem with prisoners. However, following a review of the literature in 2005 using the 
key words: adherence or compliance or concordance; schizophrenia or schizoaffective 
disorder; antipsychotic or neuroleptic; medication; prison, no high quality empirical 
studies were found that had examined adherence with antipsychotic medication in people 
with schizophrenia or schizoaffective disorder in prison. Thus a pilot study was planned 
which formed part of the Network programme of demonstration projects. 
 
It aimed to estimate the prevalence of non-adherence to antipsychotic medication in 
population of people with schizophrenia or schizoaffective disorder in prison; to 
determine prisoners’ satisfaction with and beliefs and attitudes towards such medication; 
to determine predictors of adherence amongst prisoners and explore prisoners’ current 
and previous subjective experiences of medication. 
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This report presents a review of the literature, the methodology and the research design 
for the study. The findings from the interviews in terms of the quantitative and qualitative 
elements are presented and the implications discussed. The way forward for further 
research is considered. 
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Literature review 
 Method 
This literature review sought to establish the various factors associated with 
adherence/satisfaction with antipsychotic medication in prisoners. The review was 
conducted by searching; CINHAL, EMBASE, Medline and PsychINFO. Articles in 
English were included irrespective of country of origin. The search strategy included all 
aspects of influences on adherence and satisfaction with antipsychotic medication in 
prisoners. The terms used were: adherence, non-adherence, compliance, non compliance, 
concordance, satisfaction, schizophrenia, psychosis, treatment, antipsychotics, 
neuroleptic, medication, prisoners, offenders, prisons (used individually and in 
combination with Boolean operators; and/or). 
 
Articles written since 1993 were included, the rationale for choosing 1993 is that this was 
when atypical antipsychotics became available and hence articles written after this time 
are more representative of the current clinical climate. Empirical studies published in 
peer reviewed journals were considered for relevance and inclusion in the review. 
 
The results of the search revealed that the main body of evidence relates to influences on 
adherence and satisfaction with a range of medicines and antipsychotics in the general 
population. Literature exists that examines adherence in prisoners taking medicines other 
than antipsychotics. However, there were no empirical studies that investigated adherence 
with antipsychotics in prisons. 
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Introduction 
Antipsychotic medication is an effective treatment for psychosis. However large numbers 
of people stop taking medication in clinical practice. Not taking medicine places clients at 
higher risk of relapse than those whose continue taking treatment as prescribed; the one 
year relapse risk for adherent clients is about 20- 30% whilst relapse rates without 
medication are around 70% (Johnson et al, 1983; Kissling & Leucht, 1999; Schooler, 
1999).  
 
In addition to relapse, stopping treatment with antipsychotics can result in re-
hospitalisation, high economic costs and poor outcomes (Perkins, 2002). People with 
psychosis in forensic settings who stop taking medication are more likely to start 
behaving in a violent and disturbed manner. The incidences of violence can increase due 
to clients acting on delusional ideation or other psychotic experiences (Stubbs & Haw, 
2001; Taylor, 1985; Link & Stueve, 1994). 
 
The terminology used when exploring medication taking behaviour is an important 
concept as this may have an impact on how a client engages with professionals and 
perceives the relationship.  
 
The term “compliance” has been used historically to describe medication taking 
behaviour and is sometimes used in studies designed to explore the reasons for not taking 
medication. “Compliance” suggests that a patient is a passive recipient of care who is 
expected to accept expert instructions from a clinician (Gasquet et al. 2006). This is often 
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viewed as a pejorative term by service users and research that predominantly looks at 
compliance tends to focus on understanding medication adherence from a professionals’ 
viewpoint. The term “adherence” also implies that a client has accepted advice to take 
medication; however this term also reflects the clients’ perspectives on taking medicines. 
“Concordance” has been used recently to describe the two-way process in deciding on 
and managing a treatment regimen. Concordance implies that the relationship between 
clinician and client is a partnership in which clients have the opportunity to express 
opinions and beliefs (Robson, 2002).  
  
A service users’ satisfaction with antipsychotic treatment will heavily influence treatment 
adherence and higher levels of treatment satisfaction will improve prognosis (DOH, 
1999). Despite the consensus that satisfaction is an important influence there is no agreed 
definition of treatment satisfaction. It has been proposed that satisfaction with treatment 
is determined by the collection of the clients’ subjective positive and negative 
experiences of treatment (Voruganti, 2002). Satisfaction is influenced by the tolerability 
and acceptability of treatment and relates to the attitudes that result from previous contact 
between client and clinician (Hellewell et al., 1999; Kane et al.; 1997). The published 
literature indicates that satisfaction with treatment is also a multi-factorial concept that is 
determined by acceptance of treatment/interventions (Jackson et al., 2001; Rofail et al., 
2005; Gray et al., 2002). 
 
The influences on adherence with treatment are complex and multi-factorial in nature. 
These influencing factors can be grouped under six main categories (WHO, 2003; 
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Kikkert et al. 2006; Puschner et al. 2006; Lambert et al. 2004; Fleischacker et al. 1994; 
Rofail et al. 2005; Mutsata et al. 2006; Lacro et al. 2002; Scott & Pope, 2002): 
 
• Illness related factors (including insight and severity of psychotic symptoms). 
• Treatment related factors (including side effects, efficacy and methods of 
administration). 
• Clinician related factors (including a lack of collaborative working, authoritative 
attitudes, problems accessing clinicians and infrequent medication review). 
• Patient related factors (including age, gender, beliefs about treatment and 
perceptions of illness severity).  
• Environmental factors (including family beliefs about treatment and peer 
pressure). 
• Cultural factors (patients’ ethnic background/culture).        
 
Mental health in prisons 
A review of literature about prison health care was carried out by Watson et al. (2004), 
who concluded that the aims of health care often conflict with the key tasks of the prison 
to punish and maintain order and control. Prison populations contain significantly higher 
levels of healthcare need than the general population due to the high prevalence not only 
of mental disorder, but also communicable diseases (Weild et al. 2000), chronic health 
conditions and behaviour likely to endanger health such as substance misuse (Fazel et al. 
2006), smoking and risky sexual behaviour (Marshall et al. 2000). 
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A comprehensive survey of mental health in prisons in England and Wales by Singleton 
et al. (1998) found that only one prisoner in ten showed no signs of mental disorder. Ten 
percent of men on remand and 14% of all female prisoners had demonstrated signs of 
psychosis in the year prior to the interviews in comparison with 0.4% of the general 
population. Co-morbidity in prisoners was also found to be common, with seven out of 
ten prisoners having more than one disorder and prisoners with a diagnosis of psychosis 
likely to have three or more other disorders (Meltzer et al., 1994). Fazel and Danesh 
(2002) systematically reviewed 62 prisoner surveys from 12 different countries and 
confirmed the view that mental illness in prisoners is an increasing international problem 
not confined to the UK.  
 
Suicide is a major risk in prisons and transferring prisoners to the health care centre does 
not guarantee safety; 14% of suicides in prisons occur here (Reed, 2003; HM Inspectorate 
of Prisons, 1999). Healthcare centres rarely provide adequate levels of support and 
stimulation (HM Chief Inspector of Prisons, 2004), often due to few opportunities to 
participate in constructive activities such as work or education (Mills, 2002). 
Explanations for suicide in prison are complex and varied. Liebling (1999) suggested that 
there are three distinct types of suicide; life-sentence prisoners, the psychiatrically ill and 
‘poor copers’, who have difficulties coping with imprisonment and the pressures of 
prison life such as fear, boredom and isolation from family and friends. It is estimated 
that in around 22% of prison suicides the main motivation relates to mental illness rather 
than the pressures of living in prison or guilt about the offence (Reed, 2003; HM 
Inspectorate of Prisons, 1999).  
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 The prevalence of mental illness in prisons is perceived to be increasing and this has been 
largely attributed to the introduction of care in the community policies and the 
subsequent closure of long stay community psychiatric hospitals. Transfers to the NHS of 
prisoners with serious mental illness are often delayed for months or years due to a 
shortage of beds and disputes over the necessary level of security, funding and the 
‘treatability’ of the offender, resulting in an accumulation of prisoners with mental health 
needs (Isherwood & Parrott, 2002). The number of transfers from prison has recently 
risen to 779 in 2005, the highest level for a decade (Home Office, 2007), but this 
achievement should be seen in the context of a rapidly rising prison population. Prisoners 
who are awaiting transfer to NHS in-patient care are not detained under the Mental 
Health Act and can therefore only be given medication against their will under common 
law (Reed, 2003). A prisoner who is distressed and is refusing to take medication may 
have to wait long periods to be transferred to an NHS bed where the treatment can be 
enforced. The absence of legally enforced treatment in prisons may have an effect on 
adherence rates and how prisoners perceive treatment. 
 
It is hypothesised that there may be differences in medication adherence between the 
general population and the prison population due to a range of factors including the 
absence of legal enforcement to take medication under the Mental Health Act and the 
potential differences in relationships between clinicians and patients in a prison 
environment. There is also a possibility that coercion to take medication may be apparent 
in prisons even without the right to insist on treatment under the Mental Health Act.     
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 The desired and undesired effects of medication may also be viewed differently by 
prisoners than the general population, and it is possible that some side effects may be 
viewed as being beneficial in a prison environment.   
 
Measuring the prevalence of non-adherence  
By nature, research on adherence is complicated by measurement problems and the 
possibility that recruited subjects may be inherently more adherent than those subjects 
that refuse to participate. The measurement of adherence with treatment can prove 
difficult. Rates of adherence with treatment for individual patients are usually defined by 
a percentage of the prescribed medication dose actually taken, though this is notoriously 
difficult to ascertain. There have been many different approaches taken to measure 
adherence and these have been grouped by Osterburg & Blaschke (2005) into direct and 
indirect methods of measurement. Direct and indirect measures of adherence have both 
advantages and disadvantages. Examples of direct measures include direct observation 
and blood investigations, and indirect measures encompass patient self monitoring, pill 
counts, patient questionnaires and carer questionnaires. Due to the range of factors that 
can influence the outcomes of these measures it is suggested by Osterburg & Blaschke 
(2005) that a combination of measures should be used to enhance the accuracy of 
assessment. 
 
 
 
 20
Non-adherence in the general population 
Reviews of literature on adherence with long-term therapies have highlighted the extent 
of non-adherence with a range of treatments in the general population (WHO, 2003). The 
average rate of adherence in clients with chronic conditions is 50% and varies slightly 
between disorders for example; 30-60% for antidepressants, 43% for asthma and 37-83% 
for HIV medicines (Demyttenaere & Haddad, 2000; Reid et al. 2000; Markowitz, 2000; 
Stein et al. 2000).     
 
The World Health Organisation report on adherence concluded that non-adherence to 
long term treatment is a world wide problem. The report identifies four interacting 
determinants of adherence. The relationship with professionals and other service related 
factors are seen as being crucial. Condition related factors, patient related factors and 
treatment characteristics were also highlighted as determining adherence to treatment 
(WHO, 2003). 
  
Non-adherence in prisons  
The prevalence of non-adherence with treatment in prisons should be distinguished from 
non-adherence in the general population, due to the variations seen in treatment provision 
and clinical environments. However the evidence in this area is lacking.  
 
A US study by Farabee et al. (2004) set out to establish antipsychotic adherence rates in 
people with mental health problems who were released from prison on parole. They 
found that 70.7% of parolees tested positive for the antipsychotic drug they were 
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prescribed. These results should be treated with caution when trying to generalise to the 
UK prison population due to coercion, as the research subjects were released from prison 
on condition that they attended outpatient clinics and accepted treatment. The adherence 
rate of 70.7% relates only to the presence of antipsychotic in the blood and it is therefore 
not possible to ascertain how much and for how long the prescribed treatment was 
actually taken.        
 
Several studies have examined treatment adherence in prisons, but adherence to 
antipsychotics in prisons has not been extensively investigated.  Baillargeon et al (2000) 
assessed correlates of antidepressant medication adherence in over 5000 prisoners in 
Texas. They used a 50% adherence rate to distinguish between compliant and non-
compliant prisoners and observed prisoners whilst taking medication. The study indicates 
that, over a six month period, adherence to antidepressants (calculated as doses 
taken/doses prescribed) was estimated as 0.79, ranging between 0.74 - 0.86. These results 
also need to be treated with caution due to the potential limitations of the data collection; 
although the medication was directly administered on a dose-by-dose basis under the 
supervision of a prison officer there is no guarantee that medication put in the mouth was 
actually swallowed.         
 
Duncan and Rogers (1998) used nurse ratings of compliance to assess treatment 
adherence rates in forensic outpatients. Ninety patients within the services were 
independently assessed to determine adherence rates; the patients involved had a variety 
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of diagnoses with the most common being schizophrenia (47.2%). Of the 90 patients, 40 
were deemed compliant, 38 non-compliant and 12 partially compliant.  
 
Soto Blanco et al. (2005) examined adherence to HIV medicines in three Spanish prisons 
using a cross-sectional survey design. A non-adherence prevalence rate of 54.8% was 
established. The prevalence of non-adherence in prisons appears to generally reflect rates 
seen across all disease areas in the general population.  
 
Non-adherence with antipsychotics in the general population  
Estimates of non-adherence rates of patients with psychosis vary dramatically ranging 
from 24 to 90%. Nose et al (2003) presented findings from a systematic review to provide 
an overall estimate of treatment non-adherence in community psychiatric services. A total 
of 103 studies were included and the overall mean rate of non-adherence in a community 
setting (in a sample of 23,796 patients) was 25.78 %. Studies of typical antipsychotics 
have shown that around 40% of patients discontinue medication within one year and this 
rises to around 75% after two years (Perkins, 1999). Other studies calculate a higher non-
adherence rate of 70 -80% (Breen and Thornhill, 1998).  
 
The wide differences in estimates of adherence rates are also seen in people taking other 
types of medication. Cramer and Rosenheck’s (1998) meta-analysis determined 
adherence rates of 76% (range 60 -92%) in people with physical illnesses and 63% (range 
40 – 90%) in people taking antidepressants. The differences seen in estimates of non-
adherence reflect the differences in methodological approaches of the studies and the 
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difficulties involved with accurately measuring adherence. Adherence with medication is 
not a static state and therefore most estimates represent point prevalence rather than 
adherence rates over time. Valenstine et al. (2006) retrospectively reviewed antipsychotic 
adherence rates of 34,128 patients over 4 years, and found that around 37% were poorly 
adherent in each year and that 61% of clients had problems with adherence over the 4-
year period.   
 
No studies were found that specifically investigated non-adherence with antipsychotics in 
prisons. Due to this the most meaningful data around influences on adherence with 
antipsychotics originate from the general population. 
 
Influences on adherence with antipsychotic medication in the general population 
Research exploring influences on adherence has historically focused on patient related 
factors. Predictors of adherence highlighted more recently have centred on service 
delivery and the nature/quality of relationships with professionals. 
 
Patient and family related influences on adherence 
Studies that investigate the influences on adherence relating to the client and family also 
have opposing results. Lacro et al. (2002) carried out an extensive review of literature to 
identify risk factors responsible for medication non-adherence in patients with 
schizophrenia. Several factors were identified, including poor insight, negative attitudes 
or subjective response towards medications, and previous non-adherence. In this review 
demographic influences were not associated with adherence. However other literature 
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suggests that demographic factors do have an influence on adherence. Valenstein et al. 
(2006) identified that in the USA patients who were younger and non-white were more 
likely to have consistently poor adherence over time. 
 
In accordance with Lacro et al (2002), other studies (e.g. Razali et al. 1996) suggest that 
socio-demographic characteristics of patients were not consistently associated with 
differences in medication adherence. However, in other studies age has been found to 
have an impact on adherence behaviour (Razali et al. 1996; Agarwal et al. 1998; Dolder 
et al. 2003). Fleischhacker et al. (1994) reported that older adults were more likely to be 
non-adherent.  
 
Similarly opposing findings relating to the effects of duration of illness on adherence are 
also seen; Lacro et al. (2002) and Agarwal et al. (1998) identified that a shorter duration 
of illness is likely to be associated with non-adherence. However, Scott & Pope (2002) 
argued that longer drug treatment is associated with a greater risk of non-adherence.  
 
The nature and severity of patients’ psychopathology, such as suspiciousness, hostility, 
disorganisation and cognitive deficits has been investigated in terms of an association 
with non-adherence. Fenton et al. (1997) identified that high levels of psychopathology 
(an overall high PANNS score) was predictive of non-adherence. A recent study of 
clients with a first episode of psychosis by Kampmann et al. (2002) identified a similar 
correlation. However, it is important to note that patients who had a high score for 
positive symptoms were more likely to be adherent than those with a low positive 
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symptom score. These contradictory findings could be due to the fact that patients who 
had initially severe positive symptoms were able to identify an improvement in these 
symptoms and hence had an enhanced perception of treatment efficacy. 
 
Substance abuse is another factor that influences medication adherence in people with 
schizophrenia, since people who have co-morbid substance use find adherence more 
difficult to achieve (Bebbington, 1995; Lacro et al. 2002). The impact of substance use 
on adherence with treatment is also highlighted by Owen et al. (1996) who calculate an 8-
fold increased risk of non-adherence associated with substance use.  
 
The family members of clients appear to have an influence on whether medication is 
taken or not, especially where the client is directly cared for by the family member.  
(Razali & Yahya, 1995).  
 
Quality of life (QOL) has been investigated in terms of the relationship between QOL 
and adherence. Puschener et al. (2006) analysed baseline data gathered from a multi-
centre randomized controlled trial from 409 participants in four European sites. They 
suggested that no direct relation could be concluded between subjective perceptions of 
quality of life and adherence with treatment. However, an indirect link between QOL and 
adherence was demonstrated and direct relations between other variates and QOL was 
identified. It appears that psychopathology, level of functioning and experience of 
unwanted side effects mediate the relationship between QOL and adherence. The 
limitations of this study include: self-rating of adherence by clients, the fact that clients 
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recruited were mostly outpatients; other factors e.g. relapse and dose of medication were 
not included and may have influenced adherence. 
 
Medication/treatment related influences 
Service related factors involved in the prescribing of medicines can influence adherence 
with treatment. Studies have investigated the associations between dose regimens and 
compliance and found that adherence was inversely proportional to frequency of dose 
(Fleischhacker et al., 1994, Claxton et al., 2001).   
 
Perceptions about medication side effects, not the side effects themselves, can create 
negative reactions in psychotic patients. In a study by Scott & Pope (2002), they argued 
that the fear of side effects may result in  non-adherence rather than the actual side effects 
experienced. Thoughts about and experiences of side effects will influence how an 
individual perceives their prescribed treatment. Holzinger et al. (2002) interviewed 77 
people who were prescribed Clozapine, and found that attitudes towards psychotropic 
drugs have an influence on patients' adherence with antipsychotic treatment.  
 
Studies that examine the influence of side effects on adherence with treatment have 
opposing findings. These differences may be attributed to the changes in prescribing 
practice seen after the advent of atypical antipsychotics. A US study by Gianfrancesco et 
al (2006) examined data from the medical claim forms of over 7000 patients to try and 
establish whether treatment adherence was improved in people taking atypical 
antipsychotics in comparison to typical antipsychotics. The findings suggest that 
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adherence intensity was slightly improved in the atypical group, but the duration of 
treatment between the two groups was not statistically significant. A major weakness of 
this study is that it is a retrospective analysis of clients who are eligible for medical 
insurance. Therefore the severity of illness that the clients present with may not represent 
the severity of illness seen in state hospitals where patients are not in possession of 
insurance.        
 
A similar study by Lambert et al (2004) assessed the past and current influence of side 
effects of typical antipsychotics on adherence with treatment. A total of 213 patients with 
a diagnosis of schizophrenia were recruited and the type /severity of side effects assessed 
and correlated to adherence. Patients presenting with any side effect were more likely to 
have a negative attitude towards treatment and were more doubtful about efficacy. A 
regression analysis indicated that non-adherence was mainly influenced by negative 
attitudes towards antipsychotics and the experience of past or present antipsychotic side 
effects.   
 
Health professional related influences 
A positive therapeutic relationship with health care professionals results in higher rates of 
treatment satisfaction and the client’s perception of treatment alliance is a strong 
predictor of adherence (Awad, 2004). Patients who trust health care professionals are able 
to be more honest when discussing treatment and seem to have a more positive view of 
treatment than those who have a poor level of collaboration (Fleischhacker et al. 1994).  
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Holzinger et al. (2002) and Bjoerkman et al. (1995) reinforce this viewpoint and 
demonstrate that mental health out-patients feel that a professionals’ empathetic qualities 
were of most importance in terms of positively influencing therapeutic relationships. 
Fenton et al (1997) concluded that if a client perceives that a professional is interested in 
his/her progress then adherence to treatment will increase. Adequate time provided for 
patients is another factor that could help build positive therapeutic relationships (Ricketts, 
1996). Negative relationships can have a negative impact on medication adherence. Lacro 
et al. (2002) found that a poor therapeutic relationship reduces patients’ medication 
adherence.  
 
A recent study by Kikkert et al (2006) used concept mapping (a qualitative and 
quantitative research method) to ascertain the views of people with psychosis about 
factors affecting adherence. The findings are consistent with other recent evidence and 
highlight that the most important influences on adherence from a clients’ perspective are: 
efficacy of treatment, support from informal and formal sources, ability to self manage 
side effects and insight.   
 
It can be seen that a great deal of information exists that investigates the influences on 
taking antipsychotics in the general population. However, the difference in treatment 
settings makes the generalisibility of these results to prison environments dubious.  
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Influences on treatment adherence in prisons 
A number of studies have investigated the influences on adherence in ex-prisoners 
released into the community. The findings of these studies are relevant to this review as 
similar issues may be seen in the same client group irrespective of whether they are 
actually in prison or not. Farabee and colleagues (Farabee et al. 2004; Farabee and Shen, 
2004a) investigated patient and service related factors that influence antipsychotic 
medication taking behaviour in parolees. It was observed that patients who used cocaine 
were less likely to be adherent with treatment and more likely to re-offend than those 
who did not use cocaine. African American and younger patients were more likely to be 
non-adherent than older patients of different ethnic origins.  In terms of service related 
factors, perceived coercion was not associated with enhanced adherence. However being 
prescribed an atypical antipsychotic and having a guardian in the community resulted in 
an almost 10-fold increase in the likelihood of the parolee being tested positive for their 
prescribed antipsychotic.         
 
Adherence with treatment regimens in prisons has been explored to try and ascertain 
which factors have an influence on adherence rates. The research on influences on 
adherence in prison specific environments encompasses a wide range of medicines, with 
a significant amount of data around the use of medicines for HIV. White et al. (2006) 
assessed the health beliefs and attitudes of 65 prisoners in terms of adherence to HIV 
medicines. Multiple antiretroviral adherence measures were used to test the psychometric 
properties of the survey questionnaire piloted. The findings suggest that patients with 
positive attitudes about medicines were more adherent. In terms of reasons for missed 
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doses the most commonly cited factors were: running out of medicine (44%), being 
absent when medicine dispensed (38%), forgetting (33%), being asleep when medicine 
dispensed (33%) and nausea due to side effects (33%). The small sample size and the use 
of only one prison to recruit participants limits the ability to generalise these findings to 
HIV infected prisoners in other institutions.  
 
The relationship between the patient and professionals has an important influence on 
adherence and satisfaction with treatment in HIV positive women prisoners. Mostashari 
et al (1998) conducted structured interviews with 102 HIV infected females in the USA 
and found that trust in medications, trust in the health care system and interpersonal 
relationships with professionals/peers were significantly associated with improved  
adherence.      
 
The impact of antidepressant side effects on adherence in prisons has been explored. The 
differences in adherence rates between Tricyclic (TCA) and SSRI antidepressants in 5305 
prisons inmates was investigated by Baillargeon et al. (2000), who found that although 
adherence rates to SSRIs were slightly higher than to TCAs, there was no statistical 
significance between the groups. These findings are at odds with findings by Katzelnick 
et al (1996) and Fairman et al (1998). It is hypothesised that the differences in results 
could be attributed to prisoners perceiving benefit in the sedation side effects associated 
with TCAs whilst in a prison environment.  
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The impact of attitudes towards treatment on adherence is a reoccurring theme in the 
prison specific literature. A US study (Williams et al., 1998) examining attitudes towards 
psychiatric medications in a sample of female adolescent prisoners found that almost one 
half of the 214 subjects were doubtful of the benefits of treatment. Prior illicit drug use 
was not found to influence attitudes. However past treatment with psychiatric 
medications was associated with an enhanced perception of efficacy and acceptance of 
treatment. The strongest predictor of bias against pharmacotherapy was the idea that 
“people should solve problems on their own, medicines are a crutch”.  
 
In terms of attitudes towards treatment, similarities are seen between forensic 
environments and the general population. Jennings et al (2002) established a psycho-
education group for forensic patients in a high security setting. The effect of the group on 
attitudes towards treatment was measured and it was concluded that the education had a 
positive impact on the patients’ perceptions of treatment, and that these findings were 
broadly consistent with similar studies in non-forensic settings. 
 
Summary 
The literature highlights the high prevalence of mental illness in prisons and the high 
prevalence of treatment non-adherence in the general population. Similar rates of non-
adherence with treatment are seen in prison environments irrespective of the type of 
treatment being offered and despite the absence of enforced treatment under the Mental 
Health Act. Non-adherence with antipsychotics is associated with an increased risk of 
relapse and, in forensic settings, with an increased chance of violence. 
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 There were no high quality empirical UK published studies that examined the influences 
on antipsychotic medication adherence in prisoners. However, there are studies published 
in the USA investigating the various aspects of adherence with treatment in the prison 
system. The US studies focus on a variety of medicines rather than solely antipsychotics 
and the generalisability of findings to the UK is questionable due to the different prison 
environments and structures.  
 
Studies that explore influences on adherence with antipsychotics in the general 
population indicate that taking medication is a complex health behaviour affected by a 
range of factors including; side effects, perception of side effects, relationships with 
clinicians, attitudes/beliefs about treatment and co-morbid substance misuse. Many of the 
studies have opposing findings and fail to agree on the strongest predictors of adherence 
with treatment.  Most of the published studies confirm that attitudes towards treatment 
have a significant impact on treatment adherence, and that the nature of relationship 
between client and professional will determine how treatment is perceived. Despite 
differences in clinical environments the prevalence of non-adherence and influences on 
adherence in prisons are broadly consistent with the general population.  
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Methodology 
 Research aims 
This pilot project has aimed to:  
1. Estimate the point prevalence of non-adherence to (typical/atypical) antipsychotic 
medication in population of people with schizophrenia or schizoaffective disorder 
in prison. 
2. Determine prisoners’ satisfaction with and beliefs and attitudes towards 
antipsychotic medication.  
3. Determine predictors of adherence in prisoners with schizophrenia or schizo-
affective disorder.      
4. Compare the prevalence of adherence with a community sample of individuals 
with schizophrenia. 
5. Explore patients current and previous subjective experiences of medication 
(embedded qualitative element of project) 
 
The design 
An observational cross sectional survey design was used to investigate treatment 
adherence and satisfaction with antipsychotic medication. Cross sectional designs enable 
relationships between variables to be ascertained and comparisons to be made between 
subgroups (Fife-Schaw 1995), and thus provide a useful tool to identify potential 
predictors of adherence. Data were collected through two main methods: interviews with 
individual participants, which incorporated both quantitative clinical measures and a 
short qualitative interview, and an analysis of case notes such as Inmate Medical Records 
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(IMRs). Such mixed method approaches allow the strengths of both quantitative and 
qualitative methods to be utilised and enable both confirmatory and exploratory questions 
to be answered (Teddlie and Tashakkori 2003). In this study, the data from quantitative 
element were collected to confirm any relationships between adherence and various 
predictors of adherence, whilst the qualitative data facilitated the exploration of the 
nature of relationships between these variables. 
 
Research sites 
The research took place in three prisons which were chosen to ensure that a variety of 
prisoners could be included in the study. HMP Brixton is a category B local prison which 
serves the courts of Inner and South London and has capacity for approximately 800 
adult male remand and sentenced prisoners. HMP Winchester is a category B adult male 
local prison serving the local courts of Hampshire and the Isle of Wight, with an 
additional category C resettlement unit for longer term sentenced prisoners. It has an 
operational capacity of about 700. HMP Bronzefield is a closed female local prison 
located in Middlesex, with an operational capacity of 450. It was opened in 2004 and is 
the only private prison for female prisoners in England and Wales. 
 
Access and relation to the National Evaluation of Prison Mental Health In-Reach 
Services 
Access to research participants at HMP Bronzefield and HMP Winchester was negotiated 
as part of a larger national programme of research which seeks to evaluate the 
effectiveness of the prison mental health in-reach programme. This is taking place in five 
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sites and is funded by the NHS National R & D Programme on Forensic Mental Health. 
The third phase of the programme utilised clinical diagnostic interviews to estimate the 
prevalence of severe and enduring mental illness amongst prisoners and to examine 
whether those with severe mental illness are being offered mental health in-reach 
services. It thus provided an ideal opportunity to conduct a parallel pilot study on a 
sample of prisoners identified as having psychotic disorders and examine their 
satisfaction and adherence with their medication.  
 
To be eligible for the current study, participants needed to have been in prison for at least 
a month, have been prescribed antipsychotic medication for at least four weeks and be 
aged over 18 years. Patients with severe learning disability or organic brain disease or 
without the capacity to give written informed consent were excluded from the study. 
Ethical approval for the research was obtained from the Thames Valley multi-centre 
research ethics committee (MREC) and research governance approval was sought from 
the two NHS Trusts and one private sector company that provided mental health services 
to the three prisons. The fieldwork took place between July 2006 and April 2007. Written 
informed consent was obtained from each prisoner who agreed to participate in the study 
and the interviews were carried out by research workers trained in using the research 
instruments.  
 
In practice, few participants were actually recruited through the mental health in-reach 
study as many of the prisoners identified as having a psychotic disorder were discharged 
or transferred within four weeks of reception into prison. Thus in all three prisons an 
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alternative recruitment strategy was used. Members of mental healthcare staff, such as 
consultant psychiatrists and in-reach team leaders, were asked to identify potential 
participants who fitted the study criteria. These prisoners were then approached by the 
researchers and asked if they would like to participate in the research. Fifty-eight 
prisoners were considered to be suitable to take part in the study, 14 of whom refused to 
participate, creating a response rate of 75.9 per cent. This method of purposive sampling 
introduces a risk of bias as the mental health professionals may have been reluctant to 
identify those who had unfavourable opinions of their medication. However, it was the 
only practical method available to access potential participants within the research time 
frame.  
 
Interviews 
Interviews with participants combined two approaches to data collection: the application 
of quantitative clinical measures and a short qualitative interview.  
 
Clinical measures 
Self-report and interviewer-rated clinical measures were employed in this study to 
estimate the prevalence of adherence to antipsychotic medication, determine prisoners’ 
satisfaction, beliefs and attitudes towards their medication and to examine any 
associations between adherence and these variables.  
 
Measuring adherence is far from straightforward as definitions of adherence can vary 
widely. It may, for example, include total or partial omission, not taking the 
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recommended dose at the right time or complying with recommended medication taking 
behaviour but not agreeing with it. In this study, adherence to medication was measured 
using a composite measure of adherence, a seven-point scale which categorises 
medication taking behaviours from complete refusal (1) to active participation (7) (Kemp 
et al 1998). This has the advantage of including partial omission (for example, where 
patients are accepting only a minimum dose), but also notes whether a patient questions 
or accepts their need for treatment and takes responsibility for their treatment. It was 
supplemented by the self-report Medication Adherence Questionnaire (Morisky et al. 
1986), which consists of four questions on forgetting medication, carelessness and 
stopping medication when feeling better or worse, with affirmative answers scoring 0 and 
negative responses scoring 1. With this measure, the lower the final score, the stronger 
the adherence to medication.  
 
In order to measure respondents’ attitudes and beliefs towards antipsychotic medication, 
the Drug Attitude Inventory (DAI) (Hogan et al. 1983) was used. This is a fixed choice 
scale which consists of 30 statements, written in simple language, which respondents are 
asked to rate as true or false. Hogan et al. (1983) found that DAI ratings could accurately 
assign 89 per cent of a large outpatient sample into compliant and non-compliant groups, 
showing it to be therefore highly predictive of compliance. 
 
To measure patient satisfaction with antipsychotic medication; a factor which previous 
research has suggested is a determinant of adherence (Pellegrin et al. 2001), the 
Satisfaction with Antipsychotic Medication Scale (SWAM) (Rofail et al. 2005) was used. 
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It consists of 24 statements split into two subscales known to be related to satisfaction 
with medication; treatment acceptability (Hellewell et al. 1999, Naber and Kaspar, 2000) 
and medication insight (Awad, 1999), which participants are asked to rate using a five 
point Likert scale from ‘strongly disagree’ to ‘strongly agree’. The SWAM scale shows 
good reliability (α coefficient = 0.92 for the treatment acceptability scale and 0.84 for 
medication insight). The total score of the SWAM scale had α coefficient = 0.91, which 
ranged from 0.92-0.90 when tested in a cohort of 315 people with schizophrenia.  
 
Insight was measured using the self-report Insight Scale for Psychosis (Birchwood et al. 
1994). This is made up of an eight item scale covering three widely accepted dimensions 
of insight: perceived need for treatment, awareness of illness and relabelling symptoms as 
pathological (Tait et al. 2003); the higher the total score, the greater the level of insight. It 
demonstrates strong psychometric properties and has been widely used in research. 
 
The Liverpool University Neuroleptic Side Effects Rating Scale (LUNSERS) (Day et al. 
1995) was utilised to indicate the extent of side effects experienced by patients on 
medication. This self-report measure consists of 51 symptoms, 41 of which cover 
psychological, neurological, autonomic, hormonal and miscellaneous side effects that 
were constructed by rephrasing items from the UKU adverse events measure (Lingjaerde 
et al. 1997). The remaining ten items are ‘red-herrings’, i.e. symptoms that are not known 
to be neuroleptic side effects, which are included to ascertain whether participants are 
reporting side effects accurately or describing a high level of general symptomatology. 
Participants are asked to indicate that they have experienced a side-effect on a 0-4 scale 
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(‘not at all’, ‘very little’, ‘a little’, ‘quite a lot’, ‘very much’). The LUNSERS is easily 
understood by those using it (Walker & MacAulay 2005), and shows good test re-test 
reliability (r=0.81) and concurrent validity against the UKU (r=0.83) (Day et al. 1995). It 
has demonstrated that there is a significant but weak correlation between increasing doses 
of antipsychotic medication (measured in chlorpromazine equivalent) and the number and 
frequency of side effects measured using the LUNSERS ( r=0.31; Day et al. 1995).  
 
The Brief Psychiatric Rating Scale Expanded (BPRS- E) (Ventura et al. 1993) was 
employed to measure psychopathology. It measures four different dimensions: positive 
symptoms, negative symptoms, depression, anxiety and manic excitement/dis-
organisation, through 24 items which are rated by the interviewer on a seven point 
ordered category rating scale ranging from ‘not present’ to ‘severe’. Ten items are rated 
on the basis of interviewer observation whilst the others are based primarily on verbal 
reports from patients. It takes on average about 20 minutes to complete and is thus a 
highly efficient way of describing and evaluating of major symptom characteristics 
(Overall and Gorham 1962).  
 
Finally, to gather simple demographic data from participants such as age, ethnicity and 
history of previous contact with psychiatric services, a simple structured interview 
schedule initially created for the larger in-reach study was used. 
 
Structured measures provide a time efficient way to identify levels of adherence and 
satisfaction, and facilitate the comparison of responses across different groups of 
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individuals (Barker et al. 2002). Most of the measures used in the study rely on self-
reports from participants, which have been found to be more reliable than predictions 
from healthcare providers (Stephenson et al. 1993), but it has been suggested that patients 
tend to overestimate their compliance with neuroleptics (Kamili et al. 2001). They may 
be open to ‘social desirability bias’, whereby socially desirable behaviour or views are 
over-reported (Sudman & Bradburn, 1982), as participants rate statements according to 
what they think the researcher wants to hear. In this study, they may have been less 
willing to reveal attitudes which questioned their need for antipsychotic medication or the 
authority of mental health professionals for fear of disappointing their clinicians or of 
possible sanctions, despite assurances of confidentiality. The relationship between the 
interviewer and the participant may also affect the accuracy of self-report measures. If 
assessors have an empathetic, non-judgmental attitude and patients feel that they can trust 
them, they are more likely to feel able to report less socially desirable answers. In order 
to try and overcome any potential bias, the composite measures of adherence were 
included towards the end of the interview to allow for the development of rapport 
between the interviewer and interviewee to try and overcome any apprehension felt by 
the interviewee. Using a range of different measures within the same interview also 
provided an opportunity to test for consistency in reporting and information from self-
reported measures was corroborated with discussions with mental health professionals 
and the case note analysis (see below).  
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Qualitative interview section 
After the clinical measures had been administered, a brief qualitative interview was 
carried out. Qualitative interviews can provide access to the meanings that people 
attribute to their experiences and are likely to elicit data of greater depth and richer 
insight than more structured interviews (Miller and Glassner 1997). The qualitative part 
of the interview was used to illuminate the data from the clinical measures by exploring 
and elaborating upon significant factors which might affect satisfaction and predict 
adherence with antipsychotic medication. The interview questions were formulated in 
accordance with the aims of the research and included several issues that might affect 
adherence with medication such as views of antipsychotic medication, past experiences 
of non-adherence, medication avoidance, or relationships with healthcare professionals.  
 
A semi-structured format was employed as this provides a highly flexible approach. 
Questions are specified but the interviewer seeks clarification and elaboration of the 
answers given and participants are able to raise issues of importance to them which may 
not be listed on the interview schedule. The semi-structured format also allows a degree 
of comparability between responses (May 2001). This section of the interview lasted 
between ten and 20 minutes and, with participants’ consent, it was digitally audio-
recorded. Where this consent was not given, comprehensive notes were taken which were 
written up immediately after the interview. All audio-recorded interviews were 
transcribed verbatim with participants’ names or any other personal details removed to 
ensure anonymity. 
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Case note analysis 
Case notes including Inmate Medical Record (IMRs), mental health in-reach records and 
general prisoner records, were analysed to collect information about various potential 
predictors of adherence such as offence and prison characteristics, clinical diagnoses, 
previous psychiatric hospital admissions, medication administration and prescribing, and 
number of behavioural disturbances. To aid the collection and analysis of these data, a 
simple proforma was devised which was filled in for each patient. Although these records 
were available for every participant, as in other prison research studies such as 
Birmingham et al. (2006), IMRs were found to be an unreliable source of information as 
they frequently did not document the diagnosis given or full and accurate details of the 
medication that the participant was receiving, which were often only found in mental 
health in-reach records.  
 
Analysis 
Data from the quantitative measures were analysed using SPSS v13.0. Data were initially 
described using descriptive statistics. Demographic, prison and clinical characteristics 
and total and sub-scale scores for each of the measures (independent variables) were then 
correlated – using either spearmans rho or Pearson’s product - with the dependent 
variable medication adherence. Independent variables that were significantly correlated 
with the dependent variable were then entered into stepwise liner regression to produce a 
final statistical model.  
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The data emerging from the qualitative interview section were analysed using simple 
qualitative content analysis. A list of themes emerging from the research questions, 
interview categories and the data themselves was complied and the data were then coded 
according to these themes. They were then organised using Tesch’s (1990) method of 
‘de-contextualising’ and ‘re-contextualising’, which helps to condense and expand data 
through new organising principles. In this process, data are divided up into coded 
segments, containing one idea or piece of information. Such segments are then extracted 
from their original context and are re-contextualised by being placed in the context of the 
topic or theme that they are related to. The re-contextualised data were then analysed to 
explore relationships, patterns and connections between categories or between data 
segments coded in the same category, and also to find instances where the qualitative 
data illuminates the meaning behind the findings from the quantitative data.  
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Findings 
Demographic characteristics of the group 
The 44 prisoners in the study had a mean age of 37 years (sd=8.99; range 19-61). The 
majority of the sample were male (n=36, 82%). Over half of the participants classified 
their ethnic background as being white (n=27, 61.4%). The remaining participants 
classified themselves as being black Caribbean (n=6, 13.6%), Asian (n=6, 13.6%), other 
(n=3; 6.8%) or black African (n=2; 4.5%). The majority of prisoners did not have 
academic qualifications above the GCSE/O’level standard (n=33, 75%).  
 
Prison and offence related characteristics of the group 
The median number of previous convictions was five (mean 11.49, sd 18.75, range 0-90) 
and imprisonments three (mean 3.85, sd=4.30 range 0-20). The mean number of years 
spent in prison (both on remand and convicted) was four (median 2.5, sd 5.01, range 0.1-
23.5). On average people who participated in this study had been involved in 
behaviourial or violent disturbances on two occasions in the previous month (mean 1.78, 
median 2, s.d. 0.42, range 1-2). 
 
Clinical characteristics of the group 
All patients that took part in this study were prescribed antipsychotic medication. The 
majority of prisoners were prescribed antipsychotic medication for the treatment of a 
psychotic disorder (n=38, 86%). Six participants (14%) were prescribed antipsychotic 
medication for personality disorder. On average prisoners had been mentally ill for 10 
(s.d.=7.51) years and had been in contact with mental health services for a similar amount 
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of time (mean 9.66 years, s.d.=7.05). Most of the prisoners in the sample had had a past 
inpatient psychiatric admission (n=32, 73%). The mean number of psychiatric admissions 
was 4.23 (s.d.=6.55).  
 
All prisoners who took part in the study had an identified mental health key worker and 
the majority (n=33, 75%) attended regular (at least once a month) appointments with 
them. The majority of prisoners had a history of non-attendance at mental health 
appointments (n=24, 62%). Most prisoners were prescribed second generation 
antipsychotic medication (n=28, 64% (risperidone n=6, 14%; olanzapine n=14, 32%; 
quetiapine n=4, 9%; aripiprazole n=3, 7%; or amisulpiride n=1, 2%)) and a third (n=13, 
30%) were prescribed first generation antipsychotic medication (e.g. chlorpromazine/ 
haloperidol). Three patients (7%) were co-prescribed first and second generation 
antipsychotic medication. On average patients were prescribed 56% of the recommended 
maximum dose of antipsychotic medication (sd=.039, range 3%-125%). Oral 
administration was the most frequently used method of taking antipsychotic medication. 
Twelve (27%) prisoners were given medication as a long acting depot injection.  The 
median duration of treatment with the current antipsychotic drug was one year (mean 
3.06, sd 5.12, range .08-30). Few patients were prescribed anticholinergic (to treat 
movement disorders) (n=10, 23%) or antidepressant medication (n=5, 11%). Most 
patients were not in possession of their own medication (n=34, 77%). 
 
Table 1 shows the mean scores for adherence, treatment attitude, symptoms, satisfaction, 
side effects, insight and insight domains for the prisoners who participated in the study.  
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 Table 1. Adherence, attitude, symptoms, satisfaction, side effects and insight scores 
in the study population 
Measure Mean (SD) 
Medication adherence  
Composite measure (1-7 scale, 7=active participation) 5.09 (1.63) 
Symptoms   
BPRS-total 49.29 (14.78) 
Insight  
ISP-Total (0-12, 12=good insight) 8.27 (3.22) 
ISP-Relabel subscale (0-4, 4=good insight) 2.69 (1.15) 
ISP-Awareness of illness subscale (0-4, 4=good insight) 2.64 (1.51) 
ISP-Need for treatment subscale (0-4, 4=good insight) 2.94 (1.25) 
Treatment attitudes  
Hogan Drug Attitude Inventory (-30 to +30, +30=positive treatment 
attitudes) 
10.79 (14.31) 
Satisfaction with Medication (SWAM)  
Treatment acceptability (15-75, high score=satisfaction) 50.90 (13.69) 
Medication insight (45-9, low score=satisfaction) 22.06 (7.07) 
Medication side effects  
LUNSERS-total score (41-195) 78.23 (21.12) 
Extrapyramidal side effects (6-30) 14.23 (5.74) 
Anticholinergic side effects (5-25) 9.81 (4.25) 
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Other autonomic side effects (5-25) 7.29 (2.42) 
Allergic reactions (4-20) 6.31 (3.12) 
Psychic side effects (10-50) 23.25 (7.74) 
Hormonal side effects (6-30) 6.79 (2.41) 
Period problems (2-10) (women only n=8) 2.25 (.71) 
Miscellaneous (4-20) 8.16 (2.67) 
Red herrings (10-50) 13.82 (3.94) 
 
For the dependent variable (adherence) measured using the composite measure of 
compliance, nine prisoners rated the maximum score (active participation). Figure 1 
shows the distribution of adherence scores that are slightly to the right of a normal 
distribution. The mean score for this population is similar or slightly better than that seen 
in community samples of people with psychosis (Gray et al 2004; Gray et al 2006) and 
suggests that the population is passively accepting of medication.    
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The BPRS total score suggests that moderate levels of psychotic symptoms are present in 
this population. Scores are slightly higher than those seen in community samples (Gray et 
al 2006) perhaps suggesting that there is either more severe or more poorly managed 
illness in the prison population. The positive mean total and sub-scale scores for the 
Insight scale suggest that the population has good insight and scores for the Drug Attitude 
Inventory are indicative of a generally positive attitude towards treatment. Scores for the 
two SWAM sub-scales – treatment acceptability and medication insight – suggest that 
this population was generally satisfied with antipsychotic medication.  
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The LUNSERS total score is higher than that seen in community samples of people with 
psychosis (Gray et al 2004). Scores are particularly high for psychic side effects that 
include three items that relate to sleep and extrapyramidal side effects (i.e. movement 
disorders).  
Correlates with medication adherence 
Adherence correlated significantly and positively with need for treatment insight sub-
scale (r=.48, p<.001), insight total score (r=.384, p=.013), treatment attitudes (r=.58, 
p<.001), SWAM treatment acceptability sub-scale (r=.62, p=<.001), and LUNSERS 
miscellaneous sub-scale (r=.33, p=.029). Adherence was significantly and negatively 
correlated with prisoners being in possession of their medication (Pearson correlation= -
.38, p=.012) and SWAM medication insight (r= -.54, p<.001). No other demographic, 
prison or clinical factors correlated with adherence. Participants taking antipsychotic 
medication orally were significantly more adherent than those who were administered 
their medication via a long acting depot (tablet=5.45 vs. depot=4.17, t=2.45, p=.019). In 
prisoners taking antipsychotic medication, better adherence was associated with a past 
history of attending hospital appointments, a recognition of the need for treatment and 
positive medication insight, insight into the illness, positive drug attitudes, finding 
treatment acceptable, a lack of miscellaneous side effects (e.g. putting on weight) and 
having medication administered orally. Identifying correlates of medication adherence is 
helpful but limited, and regression modeling techniques were therefore utilised to identify 
factors that predict adherence. 
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A stepwise liner regression analysis was performed with the independent variables 
(possession of medication, history of clinic non-attendance, insight, acceptance of the 
need for treatment, treatment attitudes, SWAM medication insight, SWAM treatment 
acceptability and LUNSERS miscellaneous) that were correlated with the dependent 
variable (adherence). SWAM treatment acceptability and the LUNSERS miscellaneous 
subscale emerged as the only significant contributors towards adherence and accounted 
for 55% of the variance (adjusted R2=.55, F=8.44, p=.007). Table 2 shows the details of 
the beta coefficients for each contributing variable. 
 
Table 2. Results of the model of fit for explanatory variables of adherence 
Dependent 
variable 
Explanatory variables Standardised-
coefficient 
t p 
Adherence SWAM treatment 
acceptability 
.70 5.70 <.001 
 LUNSER miscellaneous  .36 2.91 .007 
 
Secondary analysis 
A secondary analysis was undertaken to explore which items of the SWAM treatment 
acceptability and LUNSERS miscellaneous sub-scales were correlated with adherence. 
Adherence was positively and significantly correlated with putting on weight (pearsons 
correlation=.49, p<.001) but with none of the other miscellaneous items (headaches, 
losing weight and pins and needles). Fourteen of the fifteen items from of the SWAM 
treatment acceptability sub-scale were positively and significantly correlated with 
adherence:  
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• I am involved in treatment decision (pearsons correlation =.45, p=.004) 
• If someone said I have a mental illness, they would be correct (pearsons 
correlation =.36, p=.023) 
• The consequences of not taking medication(s) are severe (pearsons correlation 
=.56, p<.001), 
• My health professional (e.g. doctors/nurses) know best (pearsons correlation =.56, 
p<.001) 
• Antipsychotic medication enables me to be independent (e.g. carry out everyday 
activities) (pearsons correlation =.54, p<.001) 
• It is important to take my antipsychotic medication even when I feel better 
(pearsons correlation =.53, p<.001) 
• My antipsychotic medication makes me feel better (pearsons correlation =.65, 
p<.001) 
• Antipsychotic medication is helpful to me (pearsons correlation =.42, p=.007) 
• I feel motivated to take my antipsychotic medication (pearsons correlation =.65, 
p<.001) 
• I am satisfied with the way health professionals (doctors/nurses) have dealt with 
the side effects of my antipsychotic medication (pearsons correlation =.37, 
p=.019) 
• I am satisfied with the outcome of my last discussion (pearsons correlation =.42, 
p<.019) 
• Antipsychotic medication prevents future problems (pearsons correlation =.34, 
p=.031)  
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• I am satisfied with the way health professionals have dealt with the side effects of 
my antipsychotic medication (pearsons correlation =.47, p=.003).  
The only SWAM-treatment acceptability item that was not correlated with adherence was 
‘it is likely that the symptoms of my illness will persist’. 
 
A second stepwise liner regression analysis was performed with the thirteen SWAM 
treatment acceptability items and the one LUNSERS item that were correlated with the 
dependent variable (adherence). Two of the SWAM items (I feel motivated to take my 
antipsychotic medication and my antipsychotic medication makes me feel better) and the 
LUNSERS item (putting on weight) accounted for 52% of the variance (adjusted R2=.52, 
F=14.67, p<.001). Table 3 shows the details of the beta coefficients for each contributing 
variable. 
Table 3. Results of the model of fit for explanatory variables of adherence 
Dependent 
variable 
Explanatory variables Standardised-
coefficient 
t P 
Adherence SWAM item – I feel 
motivated to take my 
antipsychotic medication 
.32 2.11 .042 
 SWAM item – my 
antipsychotic medication 
makes me feel better   
.36 2.41 .021 
 LUNSERS item – putting 
on weight 
.27 2.23 .032 
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Adherence and satisfaction with medication 
The quantitative data indicate that treatment acceptability is positively and significantly 
correlated with adherence, and motivation to take antipsychotic medication is a key 
explanatory variable of adherence. Responses given during the qualitative part of the 
interviews illustrate why this is the case as many participants mentioned the positive 
effects of their medication which had motivated them to take it and would continue to do 
so in the future:  
Yeah. I’m glad I take it. Because I feel a better person for it. When I’m not taking 
it all I want to do is huddle up in the cell and not see people. I become very anti-
social. (WC03)  
 
When I started taking medication, yeah I felt like a new man. I was taking that 
olanzapine and I was getting on with it, I felt really positive, I felt level headed 
and the more I stopped taking it, just my whole world fell apart again. It takes 
time for them to kick in, but when I’m not on it I’m so depressed and distressed. 
(WC06) 
 
Well at the moment, I’ve only just started Risperidone but I’m feeling the benefits 
already. The voices are a lot quieter. And they’re not so frequent. (BX02) 
 
In some cases, these positive effects were not limited to easing psychotic symptoms, but 
the antipsychotic medication also calmed them down, made them feel less anxious and 
prevented self-harm: 
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Er…. Yeah. It just calms me down and gets me on a level. It stops me cutting up 
and my mood seems to lift… (BZ01) 
 
‘Cos my thoughts are normally racing all the time and it’s slowed my thoughts 
down, but I’ve still got the clarity of thought. You know, it’s not numbed my head, 
it’s sorted of, it’s just made me feel normal. (WC12) 
 
When asked if they felt their medication was worth taking, some respondents felt that 
they needed to take it because of its capacity to prevent future problems: 
I take my medication hoping that I’m going to get better because I want to get 
better. … It does get frightening at times but I take it because I know I have to 
take it because I did once stop taking it and my world fell apart. (WC06) 
 
These findings are consistent with those from Kikkert et al. (2006) who found that 
perceived treatment efficacy was the most important factor affecting medication 
adherence. Participants who reported a history of non-adherence recounted the negative 
consequences of this, ranging from self-harm to physical symptoms, which had 
strengthened their resolve to be adherent to their medication in future: 
I disagreed with the medication that they were giving me. I was stupid, I was a 
fool to do that. I nearly lost my sanity. (WC01) 
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Whenever I don’t take it that’s when I have problems, and the reason I’m here is 
because I wasn’t taking my medicine at the time, at the time when I did what I did 
to have to come here. (BX07) 
 
When you’re bonded with six or seven people, who actually know you and talk to 
you, they saw the difference come out of me when I didn’t have my tablets and 
they were quite concerned, they said to me ‘Fucking hell, you need your tablets, 
mate’. Like straight away I’d get angry, straight away I’d get paranoid. I kept 
thinking they were talking about me and a whole aggressive side would come out 
of me which is not normal. (WC06) 
Adherence and side effects 
Research examining the side effects of antipsychotic mediation has produced 
inconclusive findings as to their direct influence on non-adherence (Scott & Pope 2002; 
Lambert 2004), and the qualitative data also revealed rather mixed opinions about side 
effects amongst the prisoners in our sample. Although they reported high scores on the 
LUNSERS scale, the impact of side effects on their attitudes to medication and adherence 
varied considerably. Just over a third felt that they had to just put up with the side effects 
and were prepared to do so in order to reap the benefits of the medication: 
You know, there’s other medicines I’ve had in the past which have had that kind 
of side effect so it don’t really matter. It’s the good it does that’s really important. 
(WC12) 
 
Well, I know it’s doing more good than it is harm so I don’t mind really. (BZ08) 
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 Others found the side effects intensely distressing and this had influenced their 
willingness to comply with their medication in the past: 
I remember taking my first depot and it must have been about 250mg of 
Haliperidol or something, which is a lot and it absolutely knocked me out. I don’t 
remember anything for about a week after, all I remember is that I’d put on 
weight. I’d grown about six times my size, and I couldn’t even lift a dustpan and 
brush in that I didn’t have any movement in my arms, in my legs and my 
thoughts… I couldn’t do anything. I was like a zombie, it was really bad. That’s 
why I’ve been refusing to get medication ever since because I just don’t agree 
with what it does to you. (BZ06) 
 
It makes me feel as though I wanna chuck it through the window, ‘cause my legs 
keep going up and down, up and down, and down. (BX05) 
Adherence and administration of medication 
Although the statistical data indicate that those who self-administer their medication are 
less adherent with treatment than those who receive it from staff, several prisoners who 
did not hold their medication in possession reported that despite their desire to take their 
medication, they were sometimes prevented from doing so as they were elsewhere in the 
prison when it was being distributed. This led to them having to make choices about 
whether to engage in other activities such as drug treatment or stay on the wing to ensure 
that they did not miss their dose: 
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Because I’ve had appointments elsewhere, because I was on the detox, they only 
give it out at certain times so I actually missed it. (WC04) 
 
It could also lead to them having to make choices about fetching their medication or their 
food: 
First time I was on the house block and I got my dinner and then I had to have 
medication so I went to get medication, but then I wanted to have my dinner. So I 
missed the medication and went back for my dinner. That’s the lunchtime meds, 
but that’s because we have to go over to the main building. I’m always worried 
that I’m not going to have my dinner.(BZ03) 
 
Not having medication in possession also meant that respondent did not have any choice 
when to take their medication, which could be a source of irritation: 
(And when were you getting the Quetiapine?) 
Morning and afternoon, even though I wanted it at night time. Not because it 
makes me feel sluggish tired but because I just know I will get a better night’s 
sleep if I take it at night time. (WC04) 
 
Research examining adherence to HIV medication in prison has also suggested that doses 
could be missed due to absence from the area where the medication is dispensed or being 
asleep when medication is administered (White et al. 2006). Whether doses of staff-
administered medication are omitted can vary according to where the prisoner is located. 
If prisoners are accommodated in the healthcare centre or another specialist setting and 
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medication is actually brought round to their cells, adherence is likely to be much more 
closely monitored by healthcare staff. If prisoners are required to collect their medication 
from a central pharmacy hatch, missed doses are more likely to occur and to go 
unnoticed. Prisoners also suggested that doses could be missed as it was sometimes too 
much trouble to go and collect their medication:  
They call you for your medication, I will do my best to go and get it, but if there’s 
too much like people queuing up, I might just miss the, miss a dose. Just because 
of the aggro of it. It’s only a tablet for God’s sake, you know what I mean. (BZ04) 
 
Whilst medication in possession is negatively correlated with adherence, staff 
administration does little to promote prisoners’ autonomy to allow them to actively 
engage in their own treatment decisions. Holding medication in possession may also help 
prisoners to get into the habit of taking it of their own accord and thus promote adherence 
in the community where it is unlikely to be administered on a daily basis. 
Adherence and the prison routine 
Just over half of the respondents who participated in the qualitative interview reported 
previous non-compliance with their medication, particularly in the community before 
they came into prison. A variety of different reasons were given for this non-adherence. 
Some participants simply forgot or were careless about taking their medication, often 
because use of other substances simply took priority: 
Because I drink a lot, as I said earlier, I used to self-medicate with cannabis and 
alcohol and some other drugs in the past. The drink has usually been my number 
one priority. (WC04) 
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 I forget because I take too much amphetamines on the out. (WC05) 
 
Substance misuse has been recognised in the research literature as a factor which can 
substantially increase the likelihood of non-adherence (Bebbington, 1995; Lacro et al. 
2002; Owen et al. 1996). Kamali et al. (2001), for example, found that comorbid 
substance misuse is significantly associated with poor compliance and can even prevent 
those patients with good insight from adhering to their medication.  
 
Two respondents on depot injections blamed their non-adherence on the way their 
medication was administered: 
It’s the actual having the injection. It’s the needle going into my bum, it’s just not 
right. I just don’t need it. It’s a hassle. The whole stigma of having to take the 
injection. (WC02) 
 
It was getting, because to begin with my CPN used to come and give it to me, give 
me an injection at my house. But then they changed it and said that I had to go to 
the Bridge Centre. To get it. And it made it hard for me to get there because I 
didn’t like going out. (BZ08) 
 
This may explain why those who take their medication orally were significantly more 
adherent than those who receive an intra-muscular injection and is consistent with the 
findings of previous studies which suggest that compliance with depot antipsychotic 
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regimens may be affected by factors which hinder attendance at depot clinics as well as 
the quality of the patient-professional relationship (Owen et al. 1996).  
 
Other respondents did not take their medication because they felt they did not need to, 
either because they were in denial about their mental health problems or because they felt 
much better: 
A bit of denial and you know, ‘I haven’t got a problem’ sort of thing. (WC08) 
 
I just didn’t want to spend the rest of my life on medication. So I guess I thought I 
was getting better so I decided to try and come off it. (WC10) 
 
One respondent was morally opposed to medication as she saw the symptoms of her 
illness, particularly the voices, as a special gift. Although she attended appointments to 
receive her depot, she made it clear that this was not because she agreed with the 
medication but because she was threatened with being sectioned if she did not: 
Yeah. I will take it to keep them happy, at the end of the day. To keep them off my 
back. I’d rather stay out of hospital than in. I’ve never been satisfied with it. I 
never will be. In the long term, if it’s keeping me out of hospital, psychiatric 
institutions, then yes I’ll continue to take it. (BZ06) 
 
Although prison and offence-related factors do not appear to be significantly correlated 
with adherence to antipsychotics among prisoners, when participants were asked if 
anything made it easier to take their medication, it became clear that the routine of prison 
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life could be beneficial, particularly for those individuals who led chaotic lifestyles 
outside. In prison, collecting or receiving their medication was as much a part of the 
routine as collecting their meals and this made it much easier to remember to take it: 
The fact that I’m in prison and it gets issued to me. And I’m told when it’s there. It 
makes it easier. (BZ02) 
 
When I was outside I used to forget the medication. I used to, don’t care about 
time. But since I’ve been to the prison I start staying with the routine all the time. 
Now everyday when they give me my medication in my room, I take it on the time. 
I take it with the food; I don’t forget. (BX01)  
 
Well, I think these spells in hospitals, where I more or less have a nurse or a 
doctor coming round saying “here’s your medication, take it” you know. Same in 
prison, you know. (BX03) 
 
For those patients with comorbid substance misuse, prison presented them with an 
opportunity not only to detox from these substances, but also to establish a healthier 
lifestyle and this may also explain why putting on weight is strongly associated with 
adherence in prison.  
 
Beyond this, being in prison appeared to have little impact on adherence. Generally, 
respondents felt that prison or healthcare staff would only detect the consequences of 
them not taking their medication rather than noticing them not taking it in the first place. 
 62
Only a small number of prisoners, particularly those accommodated in healthcare or other 
specialist units were watched whilst taking their medication due to fears of overdose: 
When the girls have finished dishing the food out, the nurse’ll go behind with his 
trolley, and there’ll be an officer standing the other side, and they give you meds 
and the officer checks your mouth. (BZ02) 
 
I don’t, I take mine. I take it in front of the nurse. I swallow it down. 
(And is that because they worry about you stashing tablets?) 
Yeah, I don’t do it now. They make me open my mouth, to open my mouth and 
show them. (BX08) 
 
Prisons do not fall under the Mental Health Act 1983 and treatment cannot be forcibly 
administered. When participants did not want to take their medication, they often simply 
refused to do so: 
I just say I'm not taking it and that’s it. They try and talk you round but if I don’t 
want to take it, I won’t and that’s it (BZ05) 
 
Only seven respondents felt that anyone would try and persuade them to take it, usually 
by talking to them and stressing the benefits of their medication, but in some cases, this 
included offering incentives: 
I think they’d offer me incentives like ‘we’ll lend you a kettle if you take your 
medicine’ or ‘come on, you’ll never get back to your own prison if you don’t take 
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your medicine’, so I think they’d used sort of social underhand measures to try 
and coax me. (WC03) 
 
I get some bribes! I get bribed to take it sometimes! Some of the staff bribe me. 
‘[name of participant] I’ll give you some cigarettes’, because I smoke tobacco in 
here, ‘I’ll give you proper cigarettes if you take your medication’ (BZ07) 
 
This same prisoner also feared that she might also be coerced into taking her medication, 
not through physical force but by being threatened with being sent to the healthcare wing 
which suffered from a noticeably restricted regime: 
They told me I’d go to healthcare which is like punishment because it’s ages bang 
up down there, yeah. They were like ‘we can make you take it’. And I was just like 
‘oh stuff that then, I’ll take it over here’. They can make me go to healthcare. 
They can. (BZ07)  
 
The inapplicability of the Mental Health Act in prisons therefore leaves prisoners able to 
decline their medication if they wish, although some prisoners may find themselves 
subject to subtler pressures to encourage them to take it. 
 
Medication insight 
Although the statistical analysis revealed a positive and significant correlation between 
adherence and insight and acceptance of the need for treatment, evidence for a 
relationship between insight and treatment adherence within the research literature is 
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inconclusive (Tait et al. 2003), and insight did not emerge as an explanatory variable in 
the regression analysis. Whilst many prisoners had insight into their need for treatment, 
few had much knowledge about the medication they were prescribed and its intended 
effects. Of those who took part in an audio recorded qualitative interview, two-thirds 
reported that no-one had ever explained to them what their medication should do or why 
they had been put on it. In cases where their medication was explained, participants had 
usually been told that their medication would reduce their psychotic symptoms, such as 
the voices they were hearing: 
They told me it’d ease up on the paranoia and create… normal thoughts rather 
than paranoid ones. (WC09) 
 
All they said was that it can, it’ll help you with the voices. That was all I was ever 
told. They never told me anything else. (BZ06) 
 
Many mentioned their desire to know more about their medication and what it was doing 
to their bodies: 
Yes, obviously they have decreased my symptoms but I’d like to know sort of what 
sort of neurological parts it stops, what nerve endings it goes to, literally the ins 
and outs of the medication. Because I suffer with paranoia I do feel like a guinea 
pig sometimes with medication. (WC04) 
 
Without this knowledge, patients may find it difficult to trust mental health professionals 
and may become suspicious of their motives. In the community, patients can find out 
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more from the patient information leaflet enclosed with their medication. In the research 
prisons, these were only available to those who were allowed to keep their medication in 
possession. Since the fieldwork ended, one prison in the study has, however, made 
considerable efforts to let patients know that information sheets are available on request 
if they wish to see one. The efficacy of this measure may be limited by prisoners’ poor 
levels of literacy, making the need for verbal explanations from mental health 
professionals still necessary and an important aspect of the therapeutic relationship. 
Relationships with mental health professionals  
Previous research has suggested that a positive therapeutic alliance with healthcare 
professionals is a strong predictor of treatment satisfaction and adherence (Awad, 2004, 
Flesichhacker et al. 1994). Participants were thus asked how they would describe their 
relationship with their key healthcare professional, usually their psychiatrist. The 
majority of respondents felt that their relationships with mental health professionals were 
good and where this was the case, this was often because they felt professionals listened 
to and acknowledged their concerns:  
Well, I’ve got complete faith in him and he’s, I think he seems, the medication 
he’s put me on is a medication that will do me some good. Will help me and he’s 
been proved right. (WC12) 
 
Very good. He’s, you know, he’ll listen and at the relevant times he’ll you know 
say what he feels, what he thinks. (WC13) 
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Yeah, he’s that kind of guy that you could ask him anything if you wanted to and 
he’d answer. He’s like the older generation, you know, and you can talk to him 
easier, can’t you? They listen more. (BZ05) 
 
He is good doctor. He understands me when I was talking to him about my 
worries about my frustration with the voices. And he didn’t send me out when I 
told him I’m experiencing some shaking, he put the lithium down. And I’m looking 
forward to seeing him again to tell him about it as well. (BX01) 
 
Professionals’ empathetic qualities have been found to be the most important in terms of 
positively influencing therapeutic relationships and encouraging adherence (Fenton et al. 
1997). Many who viewed their relationship with healthcare professionals as negative felt 
that their psychiatrist did not share their understanding of their mental health problems 
and of their medication: 
Sometimes I feel that they view my problems in a different way to the way that I 
do. It might the correct way. I’m not sure. (WC01) 
 
He don’t explain anything. He just sits down and talks about the past which is 
nothing to do with this medication. (WC11) 
 
Well I disagree with Dr XX on the anti-psychotic drug. People being immune to it 
and it not working for them, I disagree with him on that. I think that if I was on 
the right one, it would work. (BX02) 
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 Such relationships are likely to have a negative impact on medication adherence, 
particularly if patients do not understand why they have been put on certain medication or 
feel that their concerns are not being taken seriously. Adequate time for patients is 
another factor which can help to build positive therapeutic relationships (Ricketts 1996), 
and where respondents were not happy with the care received from mental health staff, 
this was often because they did not get to see their psychiatrist or CPN as much as they 
wished to: 
I’d say it’s good but the only trouble is I never have enough time with him. 
Enough time to talk things through because he’s very busy. So the consultations 
are always very short. (WC03) 
 
He’s a bit useless! He just doesn’t seem to have the time for me really. (BZ08) 
 
Without the time and opportunity to listen to patients’ concern and explain their illness 
and the need for medication, the empathetic, therapeutic relationships which research 
suggests are important in encouraging adherence are unlikely to be formed. Due to the 
heavy prevalence of mental disorder within the prison population and the corresponding 
high demand for psychiatric services, time with mental health professionals is likely to be 
strictly limited despite the recent introduction of mental health in-reach teams. 
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Suggestions for improvement 
All prisoners were asked how they felt their treatment whilst in prison could be 
improved. This question elicited mixed responses. Unsurprisingly, many wanted to see 
more of mental health staff: 
I’d like to see the psychiatrist more often. It’s taken two weeks to see a CPN but 
within three minutes of being inside this prison, I asked to see the psychiatrist 
straight away. (WC04) 
 
Just medication and one to one with the psychiatrist. At the moment I only get to 
see him once a fortnight usually now. (WC05)  
 
Or they wanted medication that was more effective in tackling their symptoms: 
I know there’s loads of these different psychotic tablets that you can take. As 
[name of CPN] told me, maybe it takes time to find the right one. That’s what she 
said to me. Maybe I’m in the process of that, like trying to find the right one. This 
one has some effects that it works a bit, but unfortunately it doesn’t resolve the 
fact that I keep on seeing things, telly’s always talking to me and things like that. 
(WC06) 
 
Others mentioned the need for more psychological input to deal with the issues they felt 
had led them to be on the medication in the first instance: 
When I came from [name of prison], they said I need intensive psychology and 
basically when I came from the hospital to here, the hospital that [name of 
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prison] had put me in, they didn’t have a psychologist they only had psychiatrists 
there. I got that stressed out one day I hung myself in the shower. And they 
couldn’t cope with that so they sent me here. And now that I'm here, the 
psychiatrist is saying they can’t treat me while I'm here, other than giving me 
medication. (WC10) 
 
I don’t know. I think I need to talk through my problems rather than be on it, do 
you know what I mean? It’s just like hiding, covering up the feelings, do you know 
what I'm saying, in the short term? The feelings are still going to be there in the 
long term. (BZ07) 
 
Well I think I should, need more counselling, you know, on a one to one basis, you 
know, as we’re having now, with a qualified counsellor, you know. I think that 
might help because I find the talking groups on a Thursday helpful you know. 
(BX03) 
 
Unfortunately, psychological help in prisons is often unavailable or severely limited due 
to a lack of psychology staff on in-reach teams and the heavy demand for such services, 
and prisoners in only one of the research establishments had access to regular 
psychological support.  
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Discussion 
In this sample of prisoners adherence scores suggested passive acceptance of treatment 
with antipsychotic medication, 20 per cent were actively participating in treatment 
decisions and taking some responsibility for treatment. Scores on the composite measure 
of adherence were comparable, and possibly slightly better than community samples of 
people with schizophrenia. This observation is consistent with studies that have examined 
medication adherence rates in prisoners with HIV and depression (Soto Blanco et al. 
2005; Baillargeon et al. 2000).  
 
One of the major limitations of this study, as with all studies that explore medication 
adherence, is possible bias in the recruitment of the sample. This was a convenience and 
not a random sample. Prisoners were invited to take part in the study and consequently a 
sample may have been recruited which was not representative of the population. 
Prisoners who were able to give written consent to participate may be more likely to take 
medication (and follow medical advice) with their medication and they may have been 
unwilling to reveal negative attitudes for fear of the repercussions (see methodology). 
Consequently our adherence estimates in this population may be overly optimistic. 
 
Adherence and demographic factors 
The demographic characteristics of participants are similar to those reported in studies of 
community samples of people with psychosis (Gray et al. 2004). In this study adherence 
was not correlated with any demographic factors (age, gender, ethnicity, academic 
attainment). There is limited evidence in the literature that shows associations between 
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certain demographic characteristics and adherence in community samples. For example, 
Valenstine et al. (2006) demonstrated that younger non-white patients were more likely 
to be non-adherent whilst Fleischacker et al. (1994) found that in their sample it was 
older patients who were more likely to take medication. Generally, however, there is little 
evidence of a clear association between demographic factors and medication adherence 
and the results of this study are consistent with this observation (Razali et al. 1996; 
Agarwal et al. 1998; Dolder et al. 2003).  
 
Adherence and prison related factors 
There was interest in whether prison related factors such as the number of years prisoners 
had spent incarcerated were related to medication adherence. However, as no correlation 
was found between any of the prison related factors measured and adherence, and as 
adherence rates in people taking antipsychotic drugs in prison and the community are 
similar, this implies that incarceration has no effect on whether people will take 
medication or on how actively involved they are in treatment decisions. Nevertheless, the 
qualitative data suggest that the prison routine may encourage adherence, particularly 
among those with substance misuse issues as it can encourage a more stable lifestyle if 
only temporarily. As the provisions of the Mental Health Act do not apply in prisons, 
treatment can not be enforced, but prisoners may be coerced into taking treatment by 
other means such as threatening to move them to an area of the prison with a more 
restricted regime, although the research suggests that this was a rare occurrence.  
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Adherence and clinical characteristics 
Prisoners in this sample were all taking antipsychotic medication, the majority for the 
treatment of psychosis. The population had been ill, and in contact with mental health 
services, for around ten years and participants had had several admissions for psychiatric 
inpatient care. The clinical characteristics of the prisoners in this sample were similar to 
those in community samples of people with schizophrenia in terms of type of medication 
prescribed, symptoms (Gray et al. 2005), satisfaction (Rofail et al. 2005), and insight 
(Mutsata et al. 2006). However, prisoners in this sample had more positive attitudes 
towards treatment and higher scores on the LUNSERS side effect scale, suggesting they 
are experiencing these symptoms more frequently than in community samples, despite 
being prescribed relatively modest doses of antipsychotic medication (Gray et al. 2004; 
Gray et al. 2005), although such side effects did not appear to affect adherence. 
 
In this study the duration of prisoners’ mental illness had no effect on their adherence 
with treatment. Agarwal et al. (1998) reported that a shorter duration of illness was 
associated with non-adherence. Scott and Pope (2002) found that the longer patients had 
been ill the less likely they were to take medication. Other authors have found, as we did, 
that duration of illness had no effect on adherence (Lacro et al. 2002). Medication 
adherence is a long term problem and there is insufficient evidence to suggest that 
interventions should be targeted at any particular point in a patients’ illness.  
 
In prison medication is either given to prisoners on a weekly or fortnightly basis for self 
administration or is administered by prison staff. Prisoners who self administered were 
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found to be less adherent with treatment. Medication self administration has been 
promoted in psychiatric inpatient units to promote independence and enable patients to 
develop competence in taking medication in the community, and in prison, it may also 
ensure that prisoners are not forced to make choices between other therapeutic activities 
such as drug treatment or collecting food and their medication. It also promotes a sense of 
responsibility for their own health and autonomy by allowing prisoners to take their 
medication at a time which suits them, which may in itself encourage adherence. 
 
An association was found between adherence and both global insight and acceptance for 
the need for treatment, one of the three sub-scales. This finding is consistent with authors 
who have reported a link between insight and adherence in people with psychosis 
(Kikkert et al. 2006). However, this link is not consistent in the literature and a number of 
authors have reported that insight is not associated with adherence (Puschner et al. 2006), 
and in the regression analysis it did not contribute to our final model. In prisoners it was 
found that it was the ‘need for treatment’ and not the ‘awareness of illness’ or ‘relabelling 
symptoms as pathological’ subscales that were correlated with adherence. This finding 
may be important as it suggests that interventions to enhance adherence are more likely to 
be effective if they focus on helping prisoners recognise the need for treatment. This also 
implies a need for a strong, positive therapeutic relationship with healthcare professionals 
to ensure that their medication is adequately explained to them. 
 
In this study psychopathology was not correlated with adherence. This observation is 
inconsistent with Puschner et al. (2006) who reported a significant relationship between 
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the two in a community sample of people with schizophrenia. Kikkert et al. (2006) 
reported in a qualitative concept mapping study that perceived efficacy of treatment was 
the most important factor affecting medication adherence. Perceived treatment efficacy 
may be a component part of patients’ satisfaction with medication. Satisfaction is a 
complex concept that may be the aggregate of patients’ positive (such as perceived 
treatment efficacy) and negative (such as perceived medication side effects) subjective 
responses to medication (Voruganti, 2002). Both satisfaction subscales (treatment 
acceptability and medication insight) were correlated with adherence, and in the 
regression model, treatment acceptability was one of two variables that explained 
medication adherence. This may suggest that it is prisoners’ perception of treatment 
(measured using the SWAM treatment acceptability subscale) rather than objective 
improvements in their symptoms (measured using the BPRS) that explain medication 
adherence.  
 
This hypothesis was explored further in a secondary analysis to examine which of the 
SWAM treatment acceptability items explained adherence. Most of the items in this 
subscale were correlated with adherence. However, in a stepwise regression analysis only 
two of them - ‘I feel motivated to take my antipsychotic medication’ and ‘my 
antipsychotic medication makes me feel better’ - significantly contributed to the final 
model. The analysis strengthens the hypothesis that it is prisoners’ perception of 
treatment efficacy that is important in influencing adherence and this is supported by the 
qualitative data which suggest that many participants valued their medication for its 
positive effects on their mental health. At a clinical level it may suggest that interventions 
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to enhance adherence should focus on helping prisoners recognise the benefits of 
medication.  
 
In this study prisoner self report of the perceived frequency of side effects was not related 
to adherence for seven of the eight sub-scales of the LUNSERS. These findings are not 
consistent with Kikkert et al. (2006) and Lambert et al. (2004) who report that perceived 
side effects of medication were an important factor that negatively affected adherence in 
community samples of patients with schizophrenia. The evidence base about the effect of 
side effects on adherence is equivocal and authors have reported that side effects have 
minimal or no relationship with adherence (Puschner et al. 2006). The miscellaneous sub-
scale of the LUNSERS was correlated with adherence. However, rather than being 
negatively correlated - that is to say the less frequent the side effect the more adherent the 
prisoner - the sub-scale was positively correlated. This observation suggests that the more 
frequent the patient perceived the side effect to be the more adherent they were, a finding 
that is at odds with the previous research. In a regression analysis this subscale was a 
significant part of our explanatory model. In a secondary analysis to determine which of 
the four LUNSERS miscellaneous items were related to adherence, only ‘putting on 
weight’ was correlated with adherence and in a second regression model this item was a 
significant explanatory variable. There are several possible explanations for this 
discrepant observation. First, this is a prison population and not a community population. 
Second, Kikkert et al. (2006), Lambert et al. (2004) and Puschner et al. (2006) did not 
examine the effect of individual side effects and it may be that some have a negative and 
others a positive effect on adherence. Finally, weight gain was not objectively assessed, 
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only prisoners’ perception of weight gain, and it is possible that if prisoners perceive that 
they are putting on weight they link this to taking an effective antipsychotic medication 
when it may be the consequence of other factors such as the prison diet and lack of 
exercise. 
 
The nature of the prison environment may have an influence on how adverse effects are 
perceived by prisoners as they may have a different impact on quality of life than 
treatment in the general population. The lack of meaningful activity and associated 
boredom may result in prisoners welcoming sedation as a side effect. Similarly, other 
side effects that would normally impact on functioning in the general population (e.g. 
weight gain) may not have such a marked effect in the prison population. 
 
Many studies have shown a link between medication adherence and attitudes towards 
treatment (Lacro et al. 2002). In this current study there was a clear relationship between 
treatment attitudes and medication adherence. However, attitudes were not significant in 
our regression model.    
 
In the final regression model three variables explained 52% of the variance in adherence; 
‘I feel motivated to take my medication’, ‘my medication makes me feel better’, and 
‘putting on weight’. Other factors that we have not measured therefore have an important 
effect on adherence. One possible variable is substance use. In community populations 
substance use has been shown to be negatively associated with adherence (Lacro et al. 
2002), and findings from the qualitative interviews suggest that substance misuse did 
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indeed affect adherence and that substance misusers were more adherent in prison as they 
could no longer easily access illicit substances. 
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Conclusion  
Medication adherence is important to enable recovery and prevent relapse. Medication 
adherence in prisoners’ prescribed antipsychotic medication is similar, and perhaps 
slightly better than that seen in community samples of people with psychosis. 
Nevertheless, only a minority of prisoners were autonomously taking responsibility for 
taking medication. In our model adherence was explained by the perceived efficacy of 
treatment, motivation to take medication and weight gain. Adherence may be enhanced in 
this population if the personal relevance of medication is increased. Interventions to 
enhance adherence with treatment in prisons should aim to improve the prisoners’ 
perceptions of treatment efficacy and the need for treatment, establish a trusting 
collaborative working relationship with mental health professionals, minimise practical 
problems collecting medication, address long-term substance misuse and explore/manage 
side effects.  
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